1. Phylogeny  
Dual specificity mitogen‐activated protein kinase kinase 4 (MAP2K4), also known as MKK4, SEK1, JNKK1, MEK4, PRKMK4, SERK1, or SKK1, is a member of the mitogen‐activated protein kinase kinase (MAP2K) family within the broad CMGC group of protein kinases. It is highly conserved across eukaryotic species, with orthologs identified from yeast and plants to mammals, thereby forming an evolutionary core of the MAPK signaling apparatus that has been maintained since the last common eukaryotic ancestor (champion2004arabidopsiskinomeafter pages 9-10, gonzalezcoronel2021aphylogeneticstudy pages 12-13). Phylogenetic studies classify MAP2K4 as part of the STE (Sterile) kinase subgroup, and sequence analyses have demonstrated that its catalytic domain and docking motifs are conserved among a diverse range of species, reflecting its pivotal role in stress signal transduction (whitmarsh2007roleofmitogenactivated pages 2-3, barr2001thecjunnterminal pages 12-14). Within mammals, MAP2K4 is closely related to its paralog MAP2K7; although both kinases activate c‐Jun N‐terminal kinases (JNKs), they display complementary substrate preferences wherein MAP2K4 preferentially phosphorylates the tyrosine residue in the Thr–Pro–Tyr activation motif of JNKs, while MAP2K7 more efficiently phosphorylates the threonine residue (whitmarsh2007roleofmitogenactivated pages 2-3, katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18). These evolutionary relationships position MAP2K4 as an ancestral kinase whose dual specificity functionality has been refined by gene duplication events and subsequent sub‐functionalization across the animal and plant kingdoms (champion2004arabidopsiskinomeafter pages 9-10, gonzalezcoronel2021aphylogeneticstudy pages 12-13).

2. Reaction Catalyzed  
MAP2K4 functions as a dual specificity protein kinase that catalyzes the transfer of a phosphate group from adenosine triphosphate (ATP) to specific serine, threonine, or tyrosine hydroxyl groups on its substrate proteins. In its physiological context, MAP2K4 principally phosphorylates the activation loops of downstream MAP kinases—specifically, the c‐Jun N‐terminal kinases (JNKs) and, under select conditions, the p38 MAP kinases—thereby generating the active phosphorylated form of these stress‐responsive kinases. The general chemical reaction can be summarized as follows: ATP + [substrate protein] → ADP + [substrate protein]-phosphate + H⁺, where the substrate protein contains critical serine/threonine or tyrosine sites within their conserved activation motifs (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, whitmarsh2007roleofmitogenactivated pages 1-2).

3. Cofactor Requirements  
The catalytic activity of MAP2K4 is dependent on the presence of divalent metal ions, with Mg²⁺ serving as the essential cofactor. Magnesium ions facilitate the proper alignment and stability of ATP within the kinase’s catalytic cleft, thereby enabling the effective transfer of the γ-phosphate group to the acceptor hydroxyl moieties present on the substrate proteins (roskoski2012erk12mapkinases pages 2-4, theodosiou2002mapkinasephosphatases pages 1-2).

4. Substrate Specificity  
MAP2K4 is characterized by its dual specificity; it phosphorylates both threonine and tyrosine residues within the conserved activation loop of its target MAP kinases. The kinase primarily recognizes the Thr–Pro–Tyr sequence motif found in JNK isoforms, exhibiting a preferential catalytic bias toward the tyrosine residue, whereas its close homolog MAP2K7 preferentially phosphorylates the threonine residue of the same motif. Detailed studies employing peptide library screens and motif enrichment analyses have underscored that the substrate specificity of MAP2K4 is governed by both its catalytic site architecture and its docking domains, which mediate high-affinity recognition of MAPK substrates such as JNK and, to a lesser extent, p38 MAP kinase isoforms (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, whitmarsh2007roleofmitogenactivated pages 2-3, johnson2023anatlasof pages 6-7). In addition to the phosphorylation motif itself, the surrounding amino acid context and docking interactions contribute to the fidelity of substrate recognition, ensuring that MAP2K4 selectively activates downstream effectors within stress-activated MAPK cascades (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4).

5. Structure  
MAP2K4 comprises 399 amino acids and demonstrates a canonical bilobal kinase structure that is typical of serine/threonine protein kinases. The enzyme exhibits 11 highly conserved subdomains that fold into two distinct lobes: a smaller N-terminal lobe primarily formed by five β-sheets and a single α-helix, and a larger C-terminal lobe dominated by α-helices. These two lobes are connected via a flexible hinge region that enables the opening and closing of the catalytic cleft where ATP binds (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, pages 2-4). The ATP-binding pocket is located in the cleft between the N- and C-lobes and is lined with conserved residues, including a glycine-rich loop that confers flexibility and contributes to nucleotide binding; the active site is further defined by a DFG (Asp–Phe–Gly) motif and a catalytic loop containing an HDR (His–Arg–Asp) sequence, both of which are essential for catalytic activity (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, roskoski2012erk12mapkinases pages 2-4).  
The activation loop, which spans the region between subdomains VII and VIII, contains a conserved phosphorylation motif (S–X–A–K–T) that is critical for the kinase’s activity. In the inactive state, MAP2K4 may adopt an autoinhibited conformation, often forming dimers that occlude substrate access; phosphorylation of residues within the activation loop by upstream MAP kinase kinase kinases (MAP3Ks) relieves this autoinhibition and promotes a conformational change into the active monomeric state (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, pages 4-6, whitmarsh2007roleofmitogenactivated pages 1-2).  
A distinctive structural feature of MAP2K4 is the presence of a conserved cysteine residue (Cys246) located immediately upstream of the DFG motif. This residue has emerged as a potential covalent attachment site for inhibitor molecules, a fact that has been exploited in recent drug discovery efforts to achieve enhanced selectivity over closely related kinases such as MAP2K7 (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4). In addition to the catalytic core, MAP2K4 is equipped with docking domains that facilitate its interactions with both upstream activators (MAP3Ks) and downstream substrates (JNKs and p38), thereby ensuring the precise assembly of the MAP kinase signaling complex (whitmarsh2007roleofmitogenactivated pages 2-3, champion2004arabidopsiskinomeafter pages 10-11).

6. Regulation  
MAP2K4 is subject to intricate regulation through multiple mechanisms that ensure the accurate relay of extracellular signals. Activation of the kinase is primarily controlled via phosphorylation of its activation loop by various upstream MAP3Ks, including apoptosis signal-regulating kinase 1 (ASK1), MEKKs, mixed-lineage kinases (MLKs), and transforming growth factor β-activated kinase 1 (TAK1). Such phosphorylation events induce a substantial conformational rearrangement that switches MAP2K4 from an autoinhibited dimeric form to an active monomeric enzyme capable of engaging its substrates (whitmarsh2007roleofmitogenactivated pages 11-12, ha2019phosphorylationdynamicsof pages 11-13).  
Post-translational modifications serve as a further layer of control over MAP2K4 activity. In addition to phosphorylation, the kinase may be subjected to ubiquitination or other modifications that affect its stability and subcellular localization, although the primary regulatory event documented in the literature is the phosphorylation within the activation loop (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, whitmarsh2007roleofmitogenactivated pages 1-2).  
Moreover, scaffold proteins play an essential role in modulating MAP2K4 activity by facilitating the formation of multi-kinase complexes. Proteins such as JNK-interacting protein 3 (JIP3) and β-arrestin-2 serve to spatially and temporally coordinate the interactions between MAP2K4 and its associated kinases, thereby enhancing signal specificity and efficiency (whitmarsh2007roleofmitogenactivated pages 11-12, barr2001thecjunnterminal pages 12-14). Finally, deactivation of MAP2K4 is achieved through dephosphorylation mediated by dual-specificity phosphatases (DUSPs), which remove the activating phosphate groups and terminate downstream signaling, although specific phosphatases targeting MAP2K4 have yet to be definitively identified (ha2019phosphorylationdynamicsof pages 11-13, theodosiou2002mapkinasephosphatases pages 1-2).

7. Function  
MAP2K4 is an essential intermediate kinase within the mitogen-activated protein kinase (MAPK) cascade that predominantly influences cellular responses to stress stimuli. Functionally, it activates c‐Jun N‐terminal kinases (JNKs), including MAPK8 (JNK1), MAPK9 (JNK2), and MAPK10 (JNK3), through dual phosphorylation of their Thr–Pro–Tyr activation motifs. In this cascade, MAP2K4 selectively targets the tyrosine residue in the activation loop—a specificity that complements the activity of its paralog MAP2K7, which preferentially phosphorylates the threonine residue. This cooperative phosphorylation by MAP2K4 and MAP2K7 is critical for the full activation of JNKs, particularly in response to a variety of stress signals, such as pro-inflammatory cytokines, ultraviolet radiation, and oxidative stress (whitmarsh2007roleofmitogenactivated pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18).  
Once activated, JNKs propagate stress signals by phosphorylating a diverse array of substrates, including transcription factors such as c-Jun, thereby modulating gene expression in processes that involve apoptosis, cell proliferation, differentiation, and inflammatory responses (barr2001thecjunnterminal pages 12-14, whitmarsh2007roleofmitogenactivated pages 10-11). Additionally, MAP2K4 is required for maintaining peripheral lymphoid homeostasis, indicating its pivotal role in the regulation of immune system dynamics (whitmarsh2007roleofmitogenactivated pages 1-2, champion2004arabidopsiskinomeafter pages 21-22).  
MAP2K4’s activity also influences signaling crosstalk; for example, its role in inducing non-canonical NF-κB signaling via mechanisms that involve the processing of NFκB precursors has been documented, underscoring the kinase’s importance in integrating multiple signaling pathways (katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18, ha2019phosphorylationdynamicsof pages 11-13). The ubiquitous expression of MAP2K4 across tissues, with notable expression in the brain and immune cells, further supports its involvement in a wide range of physiological processes governed by stress-activated signaling cascades (whitmarsh2007roleofmitogenactivated pages 1-2, champion2004arabidopsiskinomeafter pages 21-22).

8. Other Comments  
Recent chemical biology and inhibitor discovery efforts have underscored the potential of targeting MAP2K4 as a therapeutic strategy for a range of diseases. Several inhibitors, including natural products such as Genistein and synthetic small molecules based on novel scaffolds, have been identified that can modulate MAP2K4 activity; however, the high degree of sequence similarity with MAP2K7 poses challenges for achieving selective inhibition (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18). Inhibitor design has increasingly exploited structural features such as the conserved Cys246 residue located adjacent to the DFG motif, rendering covalent inhibition a promising approach (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4).  
In terms of disease associations, MAP2K4 has been implicated in diverse pathological conditions. In several cancers—such as ovarian serous carcinoma, metastatic prostate cancer, and triple-negative breast cancer—genomic alterations, deletions, and mutations in MAP2K4 have been observed, reflecting a dual role as both a tumor suppressor and a promoter of metastasis depending on the cellular context (whitmarsh2007roleofmitogenactivated pages 10-11, barr2001thecjunnterminal pages 12-14). Additionally, its role in propagating inflammatory signals further links MAP2K4 to disorders marked by aberrant stress responses and chronic inflammation (ha2019phosphorylationdynamicsof pages 11-13). Owing to its central position in stress-activated MAPK pathways, ongoing research and clinical investigations continue to explore MAP2K4 inhibitors as potential therapeutic agents for cancer and inflammatory diseases (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, roskoski2012erk12mapkinases pages 2-4).

9. References  
1. Katzengruber, L., Sander, P., & Laufer, S. “Mkk4 inhibitors—recent development status and therapeutic potential.” International Journal of Molecular Sciences, 24:7495, Apr 2023. doi:10.3390/ijms24087495. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2; katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18; katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4; katzengruber2023mkk4inhibitors—recentdevelopment pages 4-6)  
2. Whitmarsh, A. J. & Davis, R. J. “Role of mitogen‐activated protein kinase kinase 4 in cancer.” Oncogene, 26:3172-3184, May 2007. doi:10.1038/sj.onc.1210410. (whitmarsh2007roleofmitogenactivated pages 1-2, pages 11-12, pages 2-3)  
3. Barr, R. K. & Bogoyevitch, M. A. “The c-jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs).” International Journal of Biochemistry & Cell Biology, 33:1047-1063, Nov 2001. doi:10.1016/s1357-2725(01)00093-0. (barr2001thecjunnterminal pages 12-14)  
4. Cargnello, M. & Roux, P. P. “Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.” Microbiology and Molecular Biology Reviews, 75:50-83, Mar 2011. doi:10.1128/mmbr.00031-10. (cargnello2011activationandfunction pages 2-4, pages 5-6, pages 1-1)  
5. Champion, A., Kreis, M., Mockaitis, K., Mockaitis, K., Picaud, A., & Henry, Y. “Arabidopsis kinome: after the casting.” Functional & Integrative Genomics, 4:163-187, Jan 2004. doi:10.1007/s10142-003-0096-4. (champion2004arabidopsiskinomeafter pages 9-10, pages 10-11, pages 21-22, pages 11-13)  
6. González-Coronel, J. M., Rodríguez-Alonso, G., & Guevara-García, A. A. “A phylogenetic study of the members of the MAPK and MEK families across Viridiplantae.” PLOS ONE, 16:e0250584, Apr 2021. doi:10.1371/journal.pone.0250584. (gonzalezcoronel2021aphylogeneticstudy pages 12-13)  
7. Ha, J., Kang, E., Seo, J., & Cho, S. “Phosphorylation dynamics of JNK signaling: effects of dual-specificity phosphatases (DUSPs) on the JNK pathway.” International Journal of Molecular Sciences, Dec 2019. doi:10.3390/ijms20246157. (ha2019phosphorylationdynamicsof pages 11-13, pages 3-6)  
8. Johnson, J. L., Yaron, T. M., Huntsman, E. M., Kerelsky, A., Song, J., Regev, A., … & Cantley, L. C. “An atlas of substrate specificities for the human serine/threonine kinome.” Nature, 613:759-766, Jan 2023. doi:10.1038/s41586-022-05575-3. (johnson2023anatlasof pages 1-2, pages 6-7)  
9. Meister, M., Tomasovic, A., Banning, A., & Tikkanen, R. “Mitogen-activated protein (MAP) kinase scaffolding proteins: a recount.” International Journal of Molecular Sciences, 14:4854-4884, Mar 2013. doi:10.3390/ijms14034854. (meister2013mitogenactivatedprotein(map) pages 1-4)  
10. Rehfeldt, S. C. H., Majolo, F., Goettert, M., & Laufer, S. “C-jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer’s diseases.” International Journal of Molecular Sciences, Dec 2020. doi:10.3390/ijms21249677. (rehfeldt2020cjunnterminalkinase pages 11-13)  
11. Roskoski, R. “Erk1/2 MAP kinases: structure, function, and regulation.” Pharmacological Research, 66:105-143, Aug 2012. doi:10.1016/j.phrs.2012.04.005. (roskoski2012erk12mapkinases pages 2-4)  
12. Theodosiou, A. & Ashworth, A. “MAP kinase phosphatases.” Genome Biology, 3:reviews3009.1-reviews3009.10, Jun 2002. doi:10.1186/gb-2002-3-7-reviews3009. (theodosiou2002mapkinasephosphatases pages 1-2)  
13. Wang, H., Gong, M., Guo, J., Xin, H., Gao, Y., Liu, C., Dai, D. Q., & Tang, L. “Genome-wide identification of Jatropha curcas MAPK, MAPKK, and MAPKKK gene families and their expression profile under cold stress.” Scientific Reports, Nov 2018. doi:10.1038/s41598-018-34614-1. (wang2018genomewideidentificationof pages 2-4)

References

1. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2): Leon Katzengruber, Pascal Sander, and Stefan Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 12 citations and is from a peer-reviewed journal.

2. (katzengruber2023mkk4inhibitors—recentdevelopment pages 16-18): Leon Katzengruber, Pascal Sander, and Stefan Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 12 citations and is from a peer-reviewed journal.

3. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4): Leon Katzengruber, Pascal Sander, and Stefan Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 12 citations and is from a peer-reviewed journal.

4. (katzengruber2023mkk4inhibitors—recentdevelopment pages 4-6): Leon Katzengruber, Pascal Sander, and Stefan Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 12 citations and is from a peer-reviewed journal.

5. (whitmarsh2007roleofmitogenactivated pages 1-2): A J Whitmarsh and R J Davis. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene, 26:3172-3184, May 2007. URL: https://doi.org/10.1038/sj.onc.1210410, doi:10.1038/sj.onc.1210410. This article has 213 citations and is from a domain leading peer-reviewed journal.

6. (whitmarsh2007roleofmitogenactivated pages 11-12): A J Whitmarsh and R J Davis. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene, 26:3172-3184, May 2007. URL: https://doi.org/10.1038/sj.onc.1210410, doi:10.1038/sj.onc.1210410. This article has 213 citations and is from a domain leading peer-reviewed journal.

7. (whitmarsh2007roleofmitogenactivated pages 2-3): A J Whitmarsh and R J Davis. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene, 26:3172-3184, May 2007. URL: https://doi.org/10.1038/sj.onc.1210410, doi:10.1038/sj.onc.1210410. This article has 213 citations and is from a domain leading peer-reviewed journal.

8. (barr2001thecjunnterminal pages 12-14): Renae K. Barr and Marie A. Bogoyevitch. The c-jun n-terminal protein kinase family of mitogen-activated protein kinases (jnk mapks). The International Journal of Biochemistry &amp; Cell Biology, 33:1047-1063, Nov 2001. URL: https://doi.org/10.1016/s1357-2725(01)00093-0, doi:10.1016/s1357-2725(01)00093-0. This article has 397 citations.

9. (cargnello2011activationandfunction pages 2-4): Marie Cargnello and Philippe P. Roux. Activation and function of the mapks and their substrates, the mapk-activated protein kinases. Microbiology and Molecular Biology Reviews, 75:50-83, Mar 2011. URL: https://doi.org/10.1128/mmbr.00031-10, doi:10.1128/mmbr.00031-10. This article has 4026 citations and is from a domain leading peer-reviewed journal.

10. (champion2004arabidopsiskinomeafter pages 10-11): A. Champion, M. Kreis, K. Mockaitis, K. Mockaitis, A. Picaud, and Y. Henry. Arabidopsis kinome: after the casting. Functional &amp; Integrative Genomics, 4:163-187, Jan 2004. URL: https://doi.org/10.1007/s10142-003-0096-4, doi:10.1007/s10142-003-0096-4. This article has 158 citations.

11. (champion2004arabidopsiskinomeafter pages 21-22): A. Champion, M. Kreis, K. Mockaitis, K. Mockaitis, A. Picaud, and Y. Henry. Arabidopsis kinome: after the casting. Functional &amp; Integrative Genomics, 4:163-187, Jan 2004. URL: https://doi.org/10.1007/s10142-003-0096-4, doi:10.1007/s10142-003-0096-4. This article has 158 citations.

12. (champion2004arabidopsiskinomeafter pages 9-10): A. Champion, M. Kreis, K. Mockaitis, K. Mockaitis, A. Picaud, and Y. Henry. Arabidopsis kinome: after the casting. Functional &amp; Integrative Genomics, 4:163-187, Jan 2004. URL: https://doi.org/10.1007/s10142-003-0096-4, doi:10.1007/s10142-003-0096-4. This article has 158 citations.

13. (gonzalezcoronel2021aphylogeneticstudy pages 12-13): José Manuel González-Coronel, Gustavo Rodríguez-Alonso, and Ángel Arturo Guevara-García. A phylogenetic study of the members of the mapk and mek families across viridiplantae. PLOS ONE, 16:e0250584, Apr 2021. URL: https://doi.org/10.1371/journal.pone.0250584, doi:10.1371/journal.pone.0250584. This article has 6 citations and is from a peer-reviewed journal.

14. (ha2019phosphorylationdynamicsof pages 11-13): Jain Ha, Eunjeong Kang, Jihye Seo, and Sayeon Cho. Phosphorylation dynamics of jnk signaling: effects of dual-specificity phosphatases (dusps) on the jnk pathway. International Journal of Molecular Sciences, Dec 2019. URL: https://doi.org/10.3390/ijms20246157, doi:10.3390/ijms20246157. This article has 75 citations and is from a peer-reviewed journal.

15. (johnson2023anatlasof pages 6-7): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 436 citations and is from a highest quality peer-reviewed journal.

16. (meister2013mitogenactivatedprotein(map) pages 1-4): Melanie Meister, Ana Tomasovic, Antje Banning, and Ritva Tikkanen. Mitogen-activated protein (map) kinase scaffolding proteins: a recount. International Journal of Molecular Sciences, 14:4854-4884, Mar 2013. URL: https://doi.org/10.3390/ijms14034854, doi:10.3390/ijms14034854. This article has 144 citations and is from a peer-reviewed journal.

17. (whitmarsh2007roleofmitogenactivated pages 10-11): A J Whitmarsh and R J Davis. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene, 26:3172-3184, May 2007. URL: https://doi.org/10.1038/sj.onc.1210410, doi:10.1038/sj.onc.1210410. This article has 213 citations and is from a domain leading peer-reviewed journal.

18. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 436 citations and is from a highest quality peer-reviewed journal.

19. (rehfeldt2020cjunnterminalkinase pages 11-13): Stephanie Cristine Hepp Rehfeldt, F. Majolo, M. Goettert, and S. Laufer. C-jun n-terminal kinase inhibitors as potential leads for new therapeutics for alzheimer’s diseases. International Journal of Molecular Sciences, Dec 2020. URL: https://doi.org/10.3390/ijms21249677, doi:10.3390/ijms21249677. This article has 46 citations and is from a peer-reviewed journal.

20. (roskoski2012erk12mapkinases pages 2-4): Robert Roskoski. Erk1/2 map kinases: structure, function, and regulation. Pharmacological Research, 66:105-143, Aug 2012. URL: https://doi.org/10.1016/j.phrs.2012.04.005, doi:10.1016/j.phrs.2012.04.005. This article has 2093 citations and is from a highest quality peer-reviewed journal.

21. (theodosiou2002mapkinasephosphatases pages 1-2): Aspasia Theodosiou and Alan Ashworth. Map kinase phosphatases. Genome Biology, 3:reviews3009.1-reviews3009.10, Jun 2002. URL: https://doi.org/10.1186/gb-2002-3-7-reviews3009, doi:10.1186/gb-2002-3-7-reviews3009. This article has 476 citations and is from a highest quality peer-reviewed journal.

22. (wang2018genomewideidentificationof pages 2-4): Haibo Wang, Ming Gong, Junyun Guo, Hu Xin, Yong Gao, Chao Liu, Dongqin Dai, and Lizhou Tang. Genome-wide identification of jatropha curcas mapk, mapkk, and mapkkk gene families and their expression profile under cold stress. Scientific Reports, Nov 2018. URL: https://doi.org/10.1038/s41598-018-34614-1, doi:10.1038/s41598-018-34614-1. This article has 36 citations and is from a poor quality or predatory journal.